×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANIX – anixa biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANIX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/2
09:23 am
anix
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress [Yahoo! Finance]
Low
Report
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress [Yahoo! Finance]
3/2
09:10 am
anix
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Low
Report
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
2/23
08:55 am
anix
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Medium
Report
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
2/10
04:06 pm
anix
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance [Yahoo! Finance]
Medium
Report
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance [Yahoo! Finance]
2/9
08:00 am
anix
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Medium
Report
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
2/4
08:03 am
anix
Anixa Biosciences (NASDAQ:ANIX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Medium
Report
Anixa Biosciences (NASDAQ:ANIX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
2/2
09:00 am
anix
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Medium
Report
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
1/27
08:30 am
anix
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Medium
Report
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/9
08:03 am
anix
Form 8-K Anixa Biosciences Inc For: Feb 09
Low
Report
Form 8-K Anixa Biosciences Inc For: Feb 09
1/29
08:58 am
anix
Form 4 Anixa Biosciences Inc For: Jan 28 Filed by: Baskies Arnold M
Low
Report
Form 4 Anixa Biosciences Inc For: Jan 28 Filed by: Baskies Arnold M
1/28
04:16 pm
anix
Form DEF 14A Anixa Biosciences Inc For: Jan 28
Low
Report
Form DEF 14A Anixa Biosciences Inc For: Jan 28
1/12
04:06 pm
anix
Form S-8 Anixa Biosciences Inc
Medium
Report
Form S-8 Anixa Biosciences Inc
1/12
04:01 pm
anix
Form 10-K Anixa Biosciences Inc For: Oct 31
Medium
Report
Form 10-K Anixa Biosciences Inc For: Oct 31
1/6
07:48 pm
anix
Form SCHEDULE 13D/A Anixa Biosciences Inc Filed by: Catelani Michael
Low
Report
Form SCHEDULE 13D/A Anixa Biosciences Inc Filed by: Catelani Michael
1/6
07:44 pm
anix
Form 4 Anixa Biosciences Inc For: Jan 05 Filed by: Titterton Lewis H jr
Low
Report
Form 4 Anixa Biosciences Inc For: Jan 05 Filed by: Titterton Lewis H jr
1/6
07:43 pm
anix
Form 4 Anixa Biosciences Inc For: Jan 05 Filed by: KUMAR AMIT
Low
Report
Form 4 Anixa Biosciences Inc For: Jan 05 Filed by: KUMAR AMIT
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/17
Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology
13.1%
12/30 ITUS Corporation (NYSE: ANIX) had its price target lowered by analysts at B. Riley from $11.25 to $8.00. They now have a "buy" rating on the stock. 11.8%
1/14 Form 4 Anixa Biosciences Inc For: Jan 14 Filed by: KUMAR AMIT 10.4%
11/26 Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study 7.3%
1/16 Form 4 Anixa Biosciences Inc For: Jan 15 Filed by: Titterton Lewis H jr 6.9%
10/15 Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts 5.7%
12/23 Anixa Biosciences to Present at Biotech Showcase 2020 5.5%
4/27 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.8%
1/21 Form 4 Anixa Biosciences Inc For: Jan 17 Filed by: Baskies Arnold M 4.8%
8/21 Form 8-K Anixa Biosciences Inc For: Aug 21 4.6%
12/30 ITUS Corporation (NYSE: ANIX) had its price target lowered by analysts at B. Riley from $11.25 to $8.00. They now have a "buy" rating on the stock. 11.8%
1/14 Form 4 Anixa Biosciences Inc For: Jan 14 Filed by: KUMAR AMIT 10.4%
11/26 Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study 7.3%
1/16 Form 4 Anixa Biosciences Inc For: Jan 15 Filed by: Titterton Lewis H jr 6.9%
10/15 Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts 5.7%
12/23 Anixa Biosciences to Present at Biotech Showcase 2020 5.5%
4/27 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.8%
1/21 Form 4 Anixa Biosciences Inc For: Jan 17 Filed by: Baskies Arnold M 4.8%
8/21 Form 8-K Anixa Biosciences Inc For: Aug 21 4.6%
TOP News Decliners
3/9
Q1/2020 1/31/2020 EPS -0.130 ZacksConsensus -0.130 ActVsEst 0.000 - In-Line
-18.5%
12/13 Anixa Biosciences Provides Update on CAR-T Program -15.1%
4/20 Anixa Bio up 30% premarket on plan to develop COVID-19 drugs [Seeking Alpha] -12.6%
1/1 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -8.5%
3/23 ITUS Corporation (NYSE: ANIX) is now covered by analysts at Aegis. They set a "buy" rating and a $8.50 price target on the stock. -6.1%
3/24 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
7/18 Form 8-K Anixa Biosciences Inc For: Jul 12 -4.4%
6/11 Form S-3 Anixa Biosciences Inc -3.6%
1/10 Form 10-K/A Anixa Biosciences Inc For: Oct 31 -3.5%
4/20 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -3.4%
12/13 Anixa Biosciences Provides Update on CAR-T Program -15.1%
4/20 Anixa Bio up 30% premarket on plan to develop COVID-19 drugs [Seeking Alpha] -12.6%
1/1 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -8.5%
3/23 ITUS Corporation (NYSE: ANIX) is now covered by analysts at Aegis. They set a "buy" rating and a $8.50 price target on the stock. -6.1%
3/24 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
7/18 Form 8-K Anixa Biosciences Inc For: Jul 12 -4.4%
6/11 Form S-3 Anixa Biosciences Inc -3.6%
1/10 Form 10-K/A Anixa Biosciences Inc For: Oct 31 -3.5%
4/20 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: